Biodegradable High-Strength Hydrogels with Injectable Performance Based on Poly(l-Glutamic Acid) and Gellan Gum.
Zong H., Wang B., Li G., Yan S., Zhang K., Shou Y.
Animal Study, published in ACS Biomater Sci Eng (2020) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- ACS Biomater Sci Eng (2020)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 33455199
- DOI
- 10.1021/acsbiomaterials.0c00915
- Citations
- 19
Abstract (original English)
Currently, biodegradable hydrogels are one of the most promising materials in tissue engineering. From the perspective of clinical needs, hydrogels with high strength and minimally invasive implantation are preferred for the reconstruction of load-bearing tissues. In this work, a biodegradable, high-strength, and injectable hydrogel was developed by one-step photo-cross-linking of two biomacromolecules, polyethylene glycol acrylated poly(l-glutamic acid) (PLGA-APEG) and methacrylated gellan gum (GG-MA). The hydrogels, named as PLGA/GG hydrogels, exhibited high mechanical properties. The compression stress of the hydrogels was 0.53 MPa, and the fracture energy was 7.7 ± 0.2 kJ m -2 . Meanwhile, the storage modulus could reach 44.0 ± 0.6 kPa. The hydrogel precursor solution loaded with adipose-derived stem cells (ASCs) was subcutaneously injected into C57BL/6 mice and then cross-linked via in situ transdermal irradiation, which demonstrated the excellent injectability and subcutaneous gelatinization of PLGA/GG hydrogels as cell carriers. Furthermore, three-dimensional encapsulation of ASCs in hydrogels after 7, 14, and 21 days showed outstanding cytocompatibility, and the viability of ASCs was up to 84.0 ± 1.7%. The PLGA/GG hydrogels exhibited ideal behaviors of degradation, with 60 ± 5% of hydrogels degraded in phosphate buffered solution (PBS) after 11 weeks. H&E staining demon
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.